Genmab — Juli 2018
-
ROW har godt nok fart på, og får mere fart på med alcyone godkendelse i sep/okt
-
webcast JNJ http://www.investor.jnj.com/events.cfm . dont really
expect anything though -
hvad mener du??? Det ser da ud til, at vi lander i den gode ende af det interval
-
new Phase 2 study in Spain Selinexor, Bortezomib and Daratumumab in Multiple Myeloma -
https://clinicaltrials.gov/ct2/show/NCT03589222?term=daratumumab+OR+ofatumumab+OR+tisotumab&lupd_s=07%2F15%2F2018&rank=3 -
Medwatch tyrkfejl:
"Foruden omsætningstallene har Genmab også fremlagt resultater for indtjeningen, der klarede sig lidt bedre end ventet, da det justerede overskud per aktie sluttede på 2,10 dollar mod estimatet på 2,07 dollar per aktie hos analytikerne ifølge Bloomberg News." -
Jefferies fastholder købsanbefalingen af Genmab-aktien og et kursmål på 1900 kr. http://www.euroinvestor.dk/nyheder/2018/07/17/genmab-jefferies-darzalex-oeger-tilliden-til-ledelsens-forventninger/13860968
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
